Quang Pham Sells 3,500 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock

by · The Markets Daily

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) CEO Quang Pham sold 3,500 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $4.21, for a total value of $14,735.00. Following the completion of the sale, the chief executive officer directly owned 150,839 shares of the company’s stock, valued at approximately $635,032.19. This trade represents a 2.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cadrenal Therapeutics Stock Up 4.8%

Shares of Cadrenal Therapeutics stock traded up $0.19 during midday trading on Wednesday, hitting $4.14. The company’s stock had a trading volume of 83,392 shares, compared to its average volume of 62,170. The firm has a market capitalization of $11.88 million, a P/E ratio of -0.74 and a beta of 1.59. The stock has a 50-day simple moving average of $5.08 and a 200-day simple moving average of $6.73. Cadrenal Therapeutics, Inc. has a 1-year low of $3.90 and a 1-year high of $15.99.

Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.47. As a group, sell-side analysts predict that Cadrenal Therapeutics, Inc. will post -5.52 earnings per share for the current year.

Institutional Trading of Cadrenal Therapeutics

A number of institutional investors have recently bought and sold shares of the company. DRW Securities LLC acquired a new stake in Cadrenal Therapeutics during the fourth quarter valued at $171,000. Citadel Advisors LLC bought a new position in Cadrenal Therapeutics during the third quarter valued at about $274,000. Geode Capital Management LLC raised its holdings in Cadrenal Therapeutics by 14.3% during the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after buying an additional 1,818 shares in the last quarter. Finally, JPMorgan Chase & Co. bought a new position in Cadrenal Therapeutics during the third quarter valued at about $103,000. Institutional investors and hedge funds own 7.92% of the company’s stock.

Wall Street Analyst Weigh In

CVKD has been the subject of a number of research reports. HC Wainwright reduced their price objective on Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Monday, April 20th. Finally, Wall Street Zen raised Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $13.00.

Read Our Latest Stock Report on Cadrenal Therapeutics

Cadrenal Therapeutics Company Profile

(Get Free Report)

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Further Reading